1. Home
  2. SIG vs ACAD Comparison

SIG vs ACAD Comparison

Compare SIG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SIG
  • ACAD
  • Stock Information
  • Founded
  • SIG 1950
  • ACAD 1993
  • Country
  • SIG Bermuda
  • ACAD United States
  • Employees
  • SIG N/A
  • ACAD N/A
  • Industry
  • SIG Consumer Specialties
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • SIG Consumer Discretionary
  • ACAD Health Care
  • Exchange
  • SIG Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • SIG 3.8B
  • ACAD 4.3B
  • IPO Year
  • SIG N/A
  • ACAD 2004
  • Fundamental
  • Price
  • SIG $92.37
  • ACAD $24.67
  • Analyst Decision
  • SIG Buy
  • ACAD Buy
  • Analyst Count
  • SIG 6
  • ACAD 21
  • Target Price
  • SIG $100.67
  • ACAD $29.30
  • AVG Volume (30 Days)
  • SIG 1.1M
  • ACAD 1.8M
  • Earning Date
  • SIG 09-02-2025
  • ACAD 11-05-2025
  • Dividend Yield
  • SIG 1.38%
  • ACAD N/A
  • EPS Growth
  • SIG N/A
  • ACAD 615.00
  • EPS
  • SIG 3.04
  • ACAD 1.33
  • Revenue
  • SIG $6,778,700,000.00
  • ACAD $1,018,885,000.00
  • Revenue This Year
  • SIG $1.41
  • ACAD $14.01
  • Revenue Next Year
  • SIG $1.07
  • ACAD $11.72
  • P/E Ratio
  • SIG $30.48
  • ACAD $18.55
  • Revenue Growth
  • SIG N/A
  • ACAD 14.41
  • 52 Week Low
  • SIG $45.55
  • ACAD $13.40
  • 52 Week High
  • SIG $106.28
  • ACAD $26.65
  • Technical
  • Relative Strength Index (RSI)
  • SIG 59.54
  • ACAD 49.69
  • Support Level
  • SIG $90.74
  • ACAD $23.34
  • Resistance Level
  • SIG $93.24
  • ACAD $25.90
  • Average True Range (ATR)
  • SIG 3.35
  • ACAD 0.78
  • MACD
  • SIG 0.04
  • ACAD -0.28
  • Stochastic Oscillator
  • SIG 81.99
  • ACAD 40.18

About SIG Signet Jewelers Limited

Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall & Outlet.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: